Morgan Stanley Maintains Overweight on Trevi Therapeutics, Raises Price Target to $19
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $18 to $19.
Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $18 to $19.